A phyllodes tumour is a rare breast tumour composed of both epithelial and connective tissue that can be benign, borderline, or malignant. It typically occurs in women ages 40, is often rapidly enlarging and painless, and can be difficult to distinguish from fibroadenomas using scans or biopsies. Treatment involves wide local excision with margins of at least 1 cm, with lymph node assessment only if clinically suspicious. Recurrence after surgery is common, and distant spread is usually to the lungs.
A phyllodes tumour is a rare breast tumour composed of both epithelial and connective tissue that can be benign, borderline, or malignant. It typically occurs in women ages 40, is often rapidly enlarging and painless, and can be difficult to distinguish from fibroadenomas using scans or biopsies. Treatment involves wide local excision with margins of at least 1 cm, with lymph node assessment only if clinically suspicious. Recurrence after surgery is common, and distant spread is usually to the lungs.
A phyllodes tumour is a rare breast tumour composed of both epithelial and connective tissue that can be benign, borderline, or malignant. It typically occurs in women ages 40, is often rapidly enlarging and painless, and can be difficult to distinguish from fibroadenomas using scans or biopsies. Treatment involves wide local excision with margins of at least 1 cm, with lymph node assessment only if clinically suspicious. Recurrence after surgery is common, and distant spread is usually to the lungs.
• Comprised of both stromal and epithelial elements
• Can exist as ◦ Benign (1/3rd) ◦ Borderline (1/3rd) ◦ Malignant forms (1/3rd) • Occurs in the age group older than FA and younger than invasive cancer - mean age 40 • Li Fraumeni syndrome patients have an increased risk • Rapidly enlarging painless tumour • Appears like a FA in US and Mammogram • FNA and core needle biopsy are also not reliable to distinguish from FA • Local recurrence is common • Distant recurrence in lung • Treatment ◦ Wide local excision with a 1 cm margin or greater ‣ Lumpectomy ‣ Partial mastectomy ◦ No need of ALN staging or ALND unless the LNs are clinically suspicious ◦ No uniform consensus on using RT after surgery ◦ Although ER/PR positive in most tumors - no place for endocrine therapy ◦ No place for chemotherapy ◦ If recurrence in lung - treatment is similar to management of soft tissue sarcoma